WG
VYGR icon

Winton Group’s Voyager Therapeutics VYGR Stock Holding History

Winton Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-36,027
Closed -$285K – 778
2024
Q2 		$285K Sell
36,027
-38,484
-52% -$323K 0.02% 495
2024
Q1 		$694K Buy
74,511
+28,979
+64% +$245K 0.05% 419
2023
Q4 		$384K Sell
45,532
-4,094
-8% -$29.7K 0.03% 448
2023
Q3 		$385K Buy
49,626
+25,284
+104% +$231K 0.03% 396
2023
Q2 		$279K Buy
+24,342
New +$252K 0.02% 549
2021
Q4 		– Sell
-24,287
Closed -$64K – 1425
2021
Q3 		$64K Buy
24,287
+6,060
+33% +$19.7K ﹤0.01% 1302
2021
Q2 		$75K Buy
+18,227
New +$82.6K ﹤0.01% 1394
2020
Q1 		– Sell
-36,390
Closed -$508K – 1556
2019
Q4 		$508K Buy
+36,390
New +$529K 0.01% 1236

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Winton Group's VYGR Position: Q3 2024 in Review

Winton Group sold out of Voyager Therapeutics (VYGR) in Q3 2024, closing a stake of 36,027 shares — an estimated $285K sold.

Winton Group first reported a position in VYGR in Q4 2019 and held it in 8 quarters. The position peaked at $694K in Q1 2024. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • Winton Group reported no remaining Voyager Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Winton Group sold 36,027 Voyager Therapeutics shares in Q3 2024, an estimated $285K.
  • Winton Group first reported a position in Voyager Therapeutics in Q4 2019 and held it in 8 quarters.
  • Winton Group's Voyager Therapeutics position peaked at $694K in Q1 2024.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on Winton Group's 13F filing for Q3 2024, filed 12 Nov 2024.